News
PULM
1.395
+0.36%
0.005
Weekly Report: what happened at PULM last week (0831-0904)?
Weekly Report · 1d ago
Weekly Report: what happened at PULM last week (0824-0828)?
Weekly Report · 08/31 09:52
Weekly Report: what happened at PULM last week (0817-0821)?
Weekly Report · 08/24 09:52
Weekly Report: what happened at PULM last week (0810-0814)?
Weekly Report · 08/17 09:53
Pulmatrix Q2 EPS $(0.29) Up From $(0.42) YoY
Benzinga · 08/13 12:52
Pulmatrix GAAP EPS of -$0.29
Seeking Alpha · 08/13 12:17
*Pulmatrix Seeks to Out-license or Monetize Its Clinical Assets >PULM
Dow Jones · 08/13 12:17
*Pulmatrix: Form S-4 Filed Related to Merger Agreement With Eos SENOLYTIX >PULM
Dow Jones · 08/13 12:17
Press Release: Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
Dow Jones · 08/13 12:15
Weekly Report: what happened at PULM last week (0803-0807)?
Weekly Report · 08/10 09:50
Weekly Report: what happened at PULM last week (0727-0731)?
Weekly Report · 08/03 09:49
Weekly Report: what happened at PULM last week (0720-0724)?
Weekly Report · 07/27 09:52
Weekly Report: what happened at PULM last week (0713-0717)?
Weekly Report · 07/20 09:50
Weekly Report: what happened at PULM last week (0706-0710)?
Weekly Report · 07/13 09:51
Weekly Report: what happened at PULM last week (0629-0703)?
Weekly Report · 07/06 09:53
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 06/29 12:05
Weekly Report: what happened at PULM last week (0622-0626)?
Weekly Report · 06/29 09:50
Weekly Report: what happened at PULM last week (0615-0619)?
Weekly Report · 06/22 09:56
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 06/18 21:06
Weekly Report: what happened at PULM last week (0608-0612)?
Weekly Report · 06/15 09:57
More
Webull provides a variety of real-time PULM stock news. You can receive the latest news about Pulmatrix through multiple platforms. This information may help you make smarter investment decisions.
About PULM
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.